Grupo BMH

Novartis announces Oncology head to retire

Basel, December 15, 2017 - Novartis announced today that Bruno Strigini, CEO Novartis Oncology has decided to retire from Novartis and the industry for personal reasons.

Joseph Jimenez, CEO of Novartis, said: "I'd like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec® patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015. I wish him the best for his future."

Bruno Strigini will step back from the Executive Committee of Novartis by December 31, ...

15 December 2017    Subscribirse

Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study

  • Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data

  • Results were consistent across patient subgroups despite differences in disease severity, genotype or background therapy

  • New findings for crizanlizumab, a potential disease-modifying, preventive treatment option for patients with sickle cell disease, presented at ASH 2017

  • Discussions with ...
11 December 2017    Subscribirse

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

  • At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached
     
  • Grade 3/4 neurologic events occurred in 12% of patients; Grade 3/4 CRS occurred in 23% of treated patients using the Penn Grading Scale and was managed by protocol-specific algorithm
     
  • More than a quarter of patients received Kymriah in outpatient setting during JULIET trial
     
  • Cost-effectiveness and societal value of ...
10 December 2017    Subscribirse

Pioneering business approach expands healthcare in Indian villages

On a muggy Thursday in July, Chankey Kumar awoke early, as usual, in the two-bedroom home he, his wife and their infant son share with his parents, aunt, uncle, and two young cousins. He slipped on a blue collared shirt and dress pants — a formality that is unusual where he lives in a working-class neighborhood on the outskirts of Meerut, India, a city several hours north of New Delhi.

...
8 December 2017    Subscribirse

One boy’s quest to battle cancer

This story represents a specific point in time in Ryan’s journey with ALL.

In early August 2015, just two weeks into his school year, 11-year-old Ryan showed signs of what his parents thought was a typical stomach bug. But what started as a stomachache and an on- again, off-again fever turned into a shocking diagnosis of leukemia – and a battle for Ryan, his family and his healthcare team to gain control over his cancer.

When Ryan became ill, his parents, Jenny and Mike, took him to his primary care doctor for an exam and blood tests. The results showed Ryan had ...

8 December 2017    Subscribirse